AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05119062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Families in the control group will be provided with routine care, including regular antenatal check ups, one bed side education (within 24 hours after delivery), one group session with discharge precautions (3rd to 5th day postpartum), two home visits (first week and second week after discharge respectively), and two physical body check at hospital on the 30th and 42nd day postpartum. Contents of the bed side education, pre-discharge education and home visits focuses on health related information, such as postpartum care, infant care and breastfeeding, etc.
Study NCT05119062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an online intergenerational co-parenting programme+usual care
Description: The program is proposed to include five sessions, with three antenatal sessions to be offered weekly during the 34-36 weeks gestation and two postnatal sessions weekly starting from the first week after discharge from hospital. The intervention will be delivered online.The program is designed for the intergenerational co-parenting families to undertake with parents together with grandmothers. The online courses will be delivered by an online platform in the study hospital. The first session will be pushed to participants in the intervention group within 2 days (around 34 weeks gestation) after recruitment. The second and third session will be pushed around 35 and 36 weeks gestation separately. The first postnatal session will be provided around the first to second week postpartum; and second postnatal session will be provided around the third to fourth week postpartum.
Study NCT04655027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: The starting dose of roxadustat will be in accordance with the China package insert, and will depend on the body weight of the patient: 100 mg (45 to \< 60 kg) or 120 mg (≥ 60 kg) in patients on dialysis; 70 mg (40 to \< 60 kg) or 100 mg (≥ 60 kg) in non-dialysis patients.
Study NCT04655027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: The starting dose of rHuEPO will be in accordance to the dosage approved in rHuEPO China package insert (patients on weekly dose of 6000 IU \[dosing will BIW\], and patients on weekly dose of >6000 IU \[dosing will TIW\]) and on patient's haemoglobin levels.
Study NCT06073002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based concurrent exercise
Description: 3 weekly sessions of home-based concurrent exercise on non-consecutive days. Resistance exercise is comprised of lunges, hip thrusts, pushups, resistance band rows, core and performed for 3 sets with 15-20 repetitions at an RPE of 14-18 (6-20 BORG scale). Endurance exercise can be done by the mode of choice and is monitored by heartrate zones. Sessions are of low to moderate intensity (below VT2) and the duration will be slowly increased for 20-40min.
Study NCT06560957 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Time restricted eating
Description: Time restricted eating involves restricting the window in which calories are consumed to 8-10 hours, without altering diet quality or caloric intake. In this study, time restricted eating will be a consistent 10-h eating window between 06:00 and 19:00, considered an early TRE pattern, for all days of the week, as chosen by the participant. They will need to consume all food and beverages (except water) during this window for the duration of the 8-week intervention.
Study NCT06560957 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Eating ad libitum with nutritional counselling
Description: Nutritional counselling will include customized advice delivered by a registered dietician about dietary choices while allowing individuals to eat at any time of day.
Study NCT04614298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827-Active
Description: Single SC administration
Study NCT04614298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KHK4827-Placebo
Description: Single SC administration
Study NCT06343116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab injection
Description: Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Study NCT06343116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered weekly (dose of placebo depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Study NCT06343116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trifluridine/tipiracil
Description: Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest.
Study NCT06343116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Description: Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest.
Study NCT04998864 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance guided Focused ultrasound (MRgFUS)
Description: FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
Study NCT06324877 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotinamide riboside
Description: Oral capsule Nicotinamide Riboside 25mg/kg/day divided into 3 equal doses
Study NCT05191966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Anterior Quadratus Lumborum Block
Description: S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.
Study NCT05191966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: TPVB block will be performed 30 min. before general anesthesia. TPVB will be performed at T10 transverse process level, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the paravertebral space.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.
Study NCT06175286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POWERBreath Plus Medium Resistance training device
Description: 30 inspirations with the POWERBreath Plus Medium Resistance training device, twice per day for 5 weeks
Study NCT04936516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation using either McGrath or C-MAC video laryngoscopy
Study NCT04511897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: An'ningpai
Description: An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
Study NCT06312865 — intervention group
Intervention type: DEVICE
Intervention: Ophthalmic exam
Description: include best corrected visual acuity and cycloplegic refraction data
Study NCT04987866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibration device , Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China
Description: The vibration device is a reusable, handheld device with a battery-powered motor and a vibration frequency of approximately 6000 times per minute (Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China)
Study NCT05577728 — intervention group
Intervention type: DRUG
Intervention: New use of semaglutide injection
Description: New use of semaglutide injection dispensing claim is used as the exposure.
Study NCT05577728 — intervention group
Intervention type: DRUG
Intervention: New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
Description: New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference.
Study NCT06278948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TP
Description: Application full face, twice daily, in the morning and at bedtime for 4 months
Study NCT06278948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group CYS
Description: Application short contact, of thin layer once daily at bedtime for 4 months
Study NCT01493895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard hoem treatment
Description: All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.
Study NCT01493895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT-808 B-cure laser machine
Description: From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.~All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.~The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards.
Study NCT06233799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release naltrexone (XR-NTX)
Description: Once per three weeks injections of extended-release naltrexone
Study NCT06233799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release bupropion (BUP-XL) tablets (BUP-XL)
Description: Daily oral extended release bupropion tablets
Study NCT06233799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iPLB
Description: Once per three weeks injections of placebo
Study NCT06233799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oPLB
Description: Daily oral placebo tablets
Study NCT06240013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling
Description: Participants will take a long sitting position on a solid and flat surface, positioning their arms back and transferring their body weight to their palms. The foam roller to be applied to the dominant side will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa, applying pressure for 2 minutes.
Study NCT06240013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Stretching
Description: A PNF stretching protocol will be implemented with each participant assuming a tall sitting position on a solid, flat surface with their knees extended as much as possible. At this moment, the participant will be asked to perform maximum isometric hamstring muscle contraction for 5 seconds, followed by 5 seconds of relaxation and 20 seconds of stretching.
Study NCT06177392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary TAVI access
Description: The randomization will determine whether radial or femoral artery puncture will be employed as the secondary access in the TAVI procedure.
Study NCT06177392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary TAVI access
Description: The randomization will determine whether radial or femoral artery puncture will be employed as the secondary access in the TAVI procedure.
Study NCT05623696 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham or actual non-invasive (Magnetic) brain stimulation
Description: 5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
Study NCT05623696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham or actual non-invasive (Magnetic) brain stimulation
Description: 5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
Study NCT05623696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham or actual non-invasive (Magnetic) brain stimulation
Description: 5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
Study NCT06092567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A ( Oblique Incremental Placement Technique)
Description: In this interventional group, a Nanohybrid composite resin Nexcomp (Meta Biomed, Korea) was placed using an oblique incremental technique with increments not exceeding 2 mm in thickness.
Study NCT06092567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B (Bulk-fill Placement technique)
Description: In this group, a composite Beautifil-Bulk Restorative (SHOFU dental) was utilized for restorative purposes using a bulk-fill technique with a thickness of 4 mm
Study NCT05624151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine +Bupivacaine
Description: infraorbital nerve block by dexmedetomidine plus bupivacaine
Study NCT05624151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate + Bupivacaine
Description: infraorbital nerve block by magnesium sulphate plus bupivacaine
Study NCT05624151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: infraorbital nerve block by bupivacaine only
Study NCT05036980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: Single IV bolus
Study NCT06149325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive somatosensory stimulation (RSS)
Description: Tactile stimuli on the index finger of the intact hand, for a duration of 45 minutes
Study NCT06149325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Repetitive somatosensory stimulation (RSS)
Description: Tactile stimuli on the index finger of the intact hand, for a duration of 4 minutes spread over 45 minutes in 6 blocks of 40 seconds
Study NCT06578741 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
Description: Treatment with the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in patients with Pararenal Abdominal Aortic Aneurysms and Thoracoabdominal Aortic Aneurysms
Study NCT06033599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MORE and MI and NRT
Description: Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.
Study NCT06033599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MORE and No MI and NRT
Description: Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.
Study NCT06033599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support Group and MI and NRT
Description: Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.
Study NCT06033599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support Group and No MI and NRT
Description: Eight group support group sessions and and nicotine replacement therapy.
Study NCT05127980 — intervention group
Intervention type: OTHER
Intervention: Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments)
Description: Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).
Study NCT05127980 — intervention group
Intervention type: OTHER
Intervention: Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin)
Description: Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).
Study NCT05127980 — intervention group
Intervention type: OTHER
Intervention: Data collection: Patient reported outcome (Fatigue questionnaires)
Description: Data collection: Patient reported outcome (Fatigue questionnaires) at 6 and 12 months.
Study NCT06430476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMI
Description: A phone-based intervention containing exercises meant to reduce ruminative thoughts carried out on an experience sampling platform m-Path
Study NCT06430476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMA
Description: A phone-based exercise containing relaxation videos carried out on an experience sampling platform m-Path
Study NCT05157243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
Study NCT05157243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin Super-B Complex
Description: Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind
Study NCT05157243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super-B Complex
Description: Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind
Study NCT05157243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo tablets administered orally with food twice daily for 5 days
Study NCT05157243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Local standard of care for COVID-19
Study NCT05157243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Local standard of care for COVID-19
Study NCT05774197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for pain
Description: Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
Study NCT06723886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental arm: Olive pomace oil
Description: Participants will consume during 8 weeks either the test oil (olive pomace oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
Study NCT06723886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-oleic acid sunflower oil
Description: Participants will consume during 8 weeks either the test active comparator oil (high-oleic acid sunflower oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
Study NCT06223360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Benfotiamine
Description: 300mg benfotiamine capsules (BID, twice a day)
Study NCT06223360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Benfotiamine
Description: 600mg benfotiamine capsules (BID, twice a day)
Study NCT06223360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to mimic benfotiamine capsules (BID, twice a day)
Study NCT04822779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonopuls 490u, Enraf-Nonius, Rotterdam, Kingdom of the Netherlands
Description: Ultrasound therapy will be applied in continuous output, 1 MHz frequency, the intensity of 1.5 W / cm2, and duration 10 min per treatment, on the front of the shoulder, on the surface of 2 ultrasound heads (10 cm2).~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus.
Study NCT04822779 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sham ultrasound therapy will be applied using a frequency of 0 Hz, intensity 0 W / cm2, 10 min per treatment.~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus.
Study NCT05420233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRE
Description: Magnetic Resonance Enterography at year 1 (in some patients)
Study NCT05183776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional administration device
Description: The novel fractional administration device enable the administration of the microspheres in fractions determined by the user. For this study, 5 fractions of 20% will be administered and validated using MRI.